Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 1(1); 2001 > Article
Case Report A Case of Advanced Hepatocellular Carcinoma(TNM Ⅳ) with Dramatic Response to Therapy
Jae Hong Park1, Soon Ho Um1, Ho Sang Ryu1, Sung Ok Suh 2, Yun Hwan Kim3
Journal of Liver Cancer 2001;1(1):98-102
DOI: https://doi.org/
Published online: June 30, 2001
1Department of Internal Medicine, Korea University College of Medicine
2Department of General surgery, Korea University College of Medicine
3Department of Diagnostic Radiology, Korea University College of Medicine
Corresponding author:  Soon Ho Um,
Email: kumcge@chollian.net
  • 493 Views
  • 4 Download
  • 0 Crossref
  • 0 Scopus

A 52 year-old-male patient with liver cirrhosis was admitted due to right upper quadrant abdominal pain for 2 month. Recently, he had been diagnosed hepatocellular carcinoma on abdominal sono and CT of local hospital. Physical findings revealed that he had mild tenderness on right upper quadrant without jaundice and hepatomegaly with 2FB. Total bilirubin was 1.1 mg/dL, AST/ALT was 57/15 IU/L, and AFP was 235,000 ng/ml. Abdomen CT scan showed 13X13cm sized mass involving chiefly right liver lobe with tumor thrombi involving right portal system and main portal trunk without arterioportal shunt. Small daughter nodule was seen in Lt. Lobe, about 1.5cm in diameter. CTAP showed perfusion defect involving chiefly right liver lobe with tumor thrombi and small daughter nodule in Lt. Lobe. CTHA showed enhacing mass involving same site. Celiac angiogram showed hypervascular tumor involving right liver lobe and no evidence of remarkable arterial portal shunt, so he was treated with TACE. During 15 months, he received total 9th TACE with adriamycin for 6th TACE and cisplatin for 3th TACE. After 9th TACE, there were no remnant survived tumor and portal vein thrmbosis. Primary lesion decreased to 5×4cm sized mass with partial response and AFP returned to normal level from 235,000 mg/ml after treatment.


JLC : Journal of Liver Cancer